BST Trade Alert
BST Trade Alert: February 19, 2013
February 19, 2013 Recommendation: Buy Vical (NASDAQ: VICL) up to $3.85 per share. About the Company: Vical is a biotech we’ve traded before with good success. Last October, we had you close out a two-month trade in the stock for a quick 22% gain! And it’s a good thing we did. After you took your profits off the […]
BST Special Trade Update: December 30, 2013
December 30, 2013 ***Special Trade Update***Hey folks, With 2013 quickly drawing to a close, I’d like to take a few minutes to share my thoughts about a biotech stock that I’m particularly excited about for 2014. You see, if all goes as planned with a certain company’s leading drug candidate, its stock price could […]
BST Trade Alert: December 19, 2013
December 19, 2013 Recommendation: Buy Conatus Pharmaceuticals (NASDAQ: CNAT) up to $7.00 per share. About the Company: Conatus is an innovative biotech focusing on the development of novel medicines to treat liver disease. The company was founded in 2005, but it just completed its initial public offering in July 2013. In other words, Conatus is not only […]
BST Trade Alert: November 26, 2013
November 26, 2013 Recommendation: Buy Venaxis (NASDAQ: APPY) up to $2.15 per share. About the Company: Venaxis is a Colorado-based biotech that was initially formed in 2000 to produce purified proteins for diagnostic applications. Since then, the company’s mission has evolved into developing diagnostic products with high profit margin potential. The company’s leading product candidate is a […]
BST Trade Alert: October 17, 2013
October 17, 2013 Recommendation: Buy Prana Biotechnology (NASDAQ: PRAN) up to $4.40 per share. About the Company: Prana is a stock that we’ve traded before with great success. Back in October 2012, we closed out a trade in this exciting biotech for a terrific 55% gain. Now, we have an opportunity for even better returns. I’ll explain […]
BST Trade Alert: September 3, 2013
September 3, 2013 Recommendation: Buy Cyclacel Pharmaceuticals (NASDAQ: CYCC) up to $3.40 per share. About the Company: Cyclacel is a fascinating company with big upside potential. This tiny biotech is pioneering orally available, small-molecule drugs that target the various phases of cell cycle control. It’s primary disease targets are two forms of cancer, acute myeloid leukemia (AML) […]
BST Trade Alert: August 14, 2013
August 14, 2013 Recommendation: Buy GTx (NASDAQ: GTXI) up to $4.75 per share. About the Company: GTx is an exciting biotech with huge upside potential. They’re developing drugs for the treatment of cancer, cancer supportive care, and other serious medical conditions. What I find fascinating about this company is that it’s pioneering a new field in the […]
BST Trade Alert: July 25, 2013
July 25, 2013 Recommendation: Buy ImmunoCellular Therapeutics (NYSE: IMUC) up to $3.05 per share. About the Company: ImmunoCellular is an exciting biotech operating on the cutting edge of science and medicine. They’re developing immune-based therapies to treat brain cancer, ovarian cancer, and other solid tumors. Here’s a quick overview of how immunotherapy is designed to work… Our […]
BST Trade Alert: June 6, 2013
June 6, 2013 Recommendation: Buy Rockwell Medical (NASDAQ: RMTI) up to $4.40 per share. About the Company: Before we tell you all about today’s biotech pick, we’d like to briefly explain our strategy for this trade. You see, we’re taking a different approach than we normally do with our biotech recommendations. As you probably know, most of […]
BST Trade Alert: May 28, 2013
May 28, 2013 Recommendation: Buy BioLineRx (NASDAQ: BLRX) up to $1.85 per share. About the Company: BioLineRx is a fascinating Israeli biotech. The company was founded in 2003 by Teva Pharmaceuticals (NYSE: TEVA), a global leader in the generic drug industry with a market cap of $33 billion. Just four years later it completed an IPO and began trading […]
